inotuzumab
pfizer,ucb pharmaceuticals
['leukemia', 'inotuzumab']
congress | #ash22 | poster
patrice chevallier presented results of the ewall-ino phase 2 study, investigating inotuzumab ozogamicin combined with low-intensity ct in older pts with bcp-all. in a med follow up of 15mo, 38.1% of pts died. after 2nd induction, cr rate was 90% #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm